+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global CAR-T Cell Therapy Market, By Product Type, By Tumor Type, By Indication, By Treatment Type, By Targeted Antigen, By End User, By Region, Competition, Forecast and Opportunities, 2017-2027

  • ID: 5410182
  • Report
  • March 2022
  • Region: Global
  • 283 Pages
  • TechSci Research
Free Webex Call
10% Free customization
Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

FEATURED COMPANIES

  • AbbVie Inc.
  • Amgen Inc
  • Bristol Myers Squibb Co.
  • Gilead Sciences, Inc
  • Johnson & Johnson
  • Novartis International AG
Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

The Global CAR-T Cell Therapy Market value in the year 2021 was valued at USD1709 million that is anticipated to grow with CAGR of 64.66% during the forecast period, 2023-2027 to achieve market value of USD33153.30 million by 2027F. Increasing instances of cancer among the world population and thus increasing death rate due to cancer is driving the growth of the Global CAR-T Cell Therapy Market in the upcoming five years. Rapidly growing clinical trial activities, proliferative M & A activities, and lucrative IPOs are majorly responsible for the growth of the Global CAR-T Cell Therapy Market in the next five years. Consistent researches on cancer and its treatment along with the advancement in the therapeutics are further substantiating the growth of the Global CAR-T Cell Therapy Market in the future five years. Increasing demand for the effective cancer treatment for the growing number of people suffering from cancer along with the flourishing pharmaceutical industry producing products and therapies for the cancer are also responsible for the growth of the Global CAR-T Cell Therapy Market in the forecast years through 2027. Although side-effects of the CAR-T cells therapy and high cost of treatment making it unaffordable to the financially challenged population may restrain the growth of the market. Government schemes, tax incentives, along with insurance policies for the treatment and increasing number of NGOs working for providing in-expensive treatment to the patients lacking financial support may aid the growth of the Global CAR-T Cell Therapy Market in the forecast period.



The Global CAR-T Cell Therapy Market is segmented by product type, tumor type, indication, treatment type, targeted antigen, end-user, regional distribution, and competition landscape. Based on treatment type, the market is further segmented into single treatment and combination treatment. Single treatment is anticipated to hold the largest revenue shares of the market and dominate the market segment in the upcoming five years on grounds of increasing cases of cancer among the population. Increasing awareness about the cancer diagnostics and early recognition of the tests are responsible for the patients opting for single treatment. Cancer in early stages can be treated with single treatments. The combination treatments are recent developments where multiple therapies are involved together to stop the cancer tumor development, to remove the lumps, and even alter the genetic information.

Gilead Sciences Inc, Novartis International AG, Bristol Myers Squibb Company, AbbVie Inc., Cellectis SA, Amgen Inc, Pfizer Inc, Merck & Co. Inc., Intellia Therapeutics Inc., Poseida Therapeutics Inc, Johnson & Johnson, Allogene Therapeutics Inc, Autolus Therapeutics PLC, Humanigen, Inc, Sangamo Therapeutics, Inc, and among others are among the major market players in the regional platform that lead the market growth of the Global CAR-T Cell Therapy Market.

Years considered for this report:

  • Historical Years: 2017- 2020
  • Base Year: 2021
  • Estimated Year: 2022
  • Forecast Period: 2023 – 2027

Objective of the Study:

  • To analyze the market size of the Global CAR-T Cell Therapy Market from 2017 to 2020.
  • To estimate and forecast the market size of the Global CAR-T Cell Therapy Market from 2021 to 2022 and growth rate until 2027.
  • To classify and forecast the Global CAR-T Cell Therapy Market based on product type, tumor type, indication, treatment type, targeted antigen, end-user, regional distribution, and competition landscape.
  • To identify dominant region or segment in the Global CAR-T Cell Therapy Market.
  • To identify drivers and challenges for the Global CAR-T Cell Therapy Market.
  • To examine competitive developments such as expansions, new product & service launches, mergers & acquisitions, etc., in the Global CAR-T Cell Therapy Market.
  • To identify and analyze the profile of leading players operating in the Global CAR-T Cell Therapy Market.
  • To identify key sustainable strategies adopted by the market players in the Global CAR-T Cell Therapy Market.

The publisher performed both primary as well as exhaustive secondary research for this study. Initially, the publisher sourced a list of manufacturers & service providers across the globe. Subsequently, the publisher conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, the publisher could include the manufacturers & service providers which could not be identified due to the limitations of secondary research. The publisher analyzed the manufacturers & service providers, distribution channels and presence of all major players across the globe.

The publisher calculated the market size of the Global CAR-T Cell Therapy Market by using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. The publisher sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these products & services and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied.

Key Target Audience:

  • Manufacturers & service providers, suppliers
  • Distributors and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to CAR-T cell therapy
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, service providers, suppliers, partners, end-users, etc., besides allowing them in strategizing investments and capitalizing on the market opportunities.

Report Scope:


In this report, the Global CAR-T Cell Therapy Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

CAR-T Cell Therapy, By Product Type:

  • Yescarta (Axicabtagene Ciloleucel)
  • Kymriah (Tisagenlecleucel)
  • Tecartus (Brexucabtagene Autoleucel)
  • Breyanzi (Lisocabtagene Maraleucel)
  • Abecma (Idecabtagene Vicleucel)
  • Others

CAR-T Cell Therapy Market, By Tumor Type:

  • Hematological Malignancies
  • Solid Tumors

CAR-T Cell Therapy Market, By Indication:

  • Diffused Large B-Cell Lymphoma (DLBCL)
  • Acute Lymphoblastic Leukemia (ALL)
  • Follicular Lymphoma (FL)
  • Mantle Cell Lymphoma (MCL)
  • Others

CAR-T Cell Therapy Market, By Treatment Type:

  • Single Treatment
  • Combination Treatment

CAR-T Cell Therapy Market, By Targeted Antigen

  • CD19
  • BCMA
  • Others

CAR-T Cell Therapy Market, By End-User:

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Others

CAR-T Cell Therapy Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • United Kingdom
  • Switzerland
  • Italy
  • Spain
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • South America
  • Columbia
  • Brazil
  • Argentina
  • Middle East & Africa
  • Israel
  • Saudi Arabia
  • South Africa
  • UAE

Competitive Landscape


Company Profiles: Detailed analysis of the major companies present in the Global CAR-T Cell Therapy Market.

Available Customizations:


With the given market data, the publisher offers customizations according to a company’s specific needs.

Please note: With the Enterprise license, the PDF product is printable and editable and comes with a market data excel sheet.

Frequently Asked Questions about the Global CAR-T Cell Therapy Market

What is the estimated value of the Global CAR-T Cell Therapy Market?

The Global CAR-T Cell Therapy Market was estimated to be valued at $13.5 Million in 2017.

What is the growth rate of the Global CAR-T Cell Therapy Market?

The growth rate of the Global CAR-T Cell Therapy Market is 118.3%, with an estimated value of $33153.3 Million by 2027.

What is the forecasted size of the Global CAR-T Cell Therapy Market?

The Global CAR-T Cell Therapy Market is estimated to be worth $33153.3 Million by 2027.

Who are the key companies in the Global CAR-T Cell Therapy Market?

Key companies in the Global CAR-T Cell Therapy Market include Gilead Sciences, Inc, Novartis International AG, Bristol Myers Squibb Co., AbbVie Inc., Cellectis SA, Amgen Inc, Pfizer Inc., Merck & Co. Inc. and Poseida Therapeutics Inc.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc.
  • Amgen Inc
  • Bristol Myers Squibb Co.
  • Gilead Sciences, Inc
  • Johnson & Johnson
  • Novartis International AG

1. Product Overview2. Research Methodology3. Impact of COVID-19 on Global CAR-T Cell Therapy Market4. Executive Summary
5. Voice of Customers
5.1. Brand Awareness
5.2. Unmet Need and Challenges
5.3. Factors Driving the CAR-T Cell Therapy Market
6. Global CAR-T Cell Therapy Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus (Brexucabtagene Autoleucel), Breyanzi (Lisocabtagene Maraleucel), Abecma (Idecabtagene Vicleucel), Others)
6.2.2. By Tumor Type (Hematological Malignancies, Solid Tumors)
6.2.3. By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others)
6.2.4. By Treatment Type (Single Treatment, Combination Treatment)
6.2.5. By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others)
6.2.6. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
6.2.7. By Region
6.2.8. By Company
6.3. Product Market Map
7. North America CAR-T Cell Therapy Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product Type
7.2.2. By Tumor Type
7.2.3. By Indication
7.2.4. By Treatment Type
7.2.5. By Targeted Antigen
7.2.6. By End User
7.2.7. By Country
7.3. North America: Country Analysis
7.3.1. United States CAR-T Cell Therapy Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product Type
7.3.1.2.2. By Tumor Type
7.3.1.2.3. By Indication
7.3.1.2.4. By Treatment Type
7.3.1.2.5. By Targeted Antigen
7.3.1.2.6. By End User
7.3.2. Canada CAR-T Cell Therapy Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product Type
7.3.2.2.2. By Tumor Type
7.3.2.2.3. By Indication
7.3.2.2.4. By Treatment Type
7.3.2.2.5. By Targeted Antigen
7.3.2.2.6. By End User
7.3.3. Mexico CAR-T Cell Therapy Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product Type
7.3.3.2.2. By Tumor Type
7.3.3.2.3. By Indication
7.3.3.2.4. By Treatment Type
7.3.3.2.5. By Targeted Antigen
7.3.3.2.6. By End User
8. Europe CAR-T Cell Therapy Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product Type
8.2.2. By Tumor Type
8.2.3. By Indication
8.2.4. By Treatment Type
8.2.5. By Targeted Antigen
8.2.6. By End User
8.2.7. By Country
8.3. Europe: Country Analysis
8.3.1. Germany CAR-T Cell Therapy Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product Type
8.3.1.2.2. By Tumor Type
8.3.1.2.3. By Indication
8.3.1.2.4. By Treatment Type
8.3.1.2.5. By Targeted Antigen
8.3.1.2.6. By End User
8.3.2. France CAR-T Cell Therapy Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product Type
8.3.2.2.2. By Tumor Type
8.3.2.2.3. By Indication
8.3.2.2.4. By Treatment Type
8.3.2.2.5. By Targeted Antigen
8.3.2.2.6. By End User
8.3.3. Switzerland CAR-T Cell Therapy Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product Type
8.3.3.2.2. By Tumor Type
8.3.3.2.3. By Indication
8.3.3.2.4. By Treatment Type
8.3.3.2.5. By Targeted Antigen
8.3.3.2.6. By End User
8.3.4. United Kingdom CAR-T Cell Therapy Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product Type
8.3.4.2.2. By Tumor Type
8.3.4.2.3. By Indication
8.3.4.2.4. By Treatment Type
8.3.4.2.5. By Targeted Antigen
8.3.4.2.6. By End User
8.3.5. Italy CAR-T Cell Therapy Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product Type
8.3.5.2.2. By Tumor Type
8.3.5.2.3. By Indication
8.3.5.2.4. By Treatment Type
8.3.5.2.5. By Targeted Antigen
8.3.5.2.6. By End User
8.3.6. Spain CAR-T Cell Therapy Market Outlook
8.3.6.1. Market Size & Forecast
8.3.6.1.1. By Value
8.3.6.2. Market Share & Forecast
8.3.6.2.1. By Product Type
8.3.6.2.2. By Tumor Type
8.3.6.2.3. By Indication
8.3.6.2.4. By Treatment Type
8.3.6.2.5. By Targeted Antigen
8.3.6.2.6. By End User
9. Asia-Pacific CAR-T Cell Therapy Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product Type
9.2.2. By Tumor Type
9.2.3. By Indication
9.2.4. By Treatment Type
9.2.5. By Targeted Antigen
9.2.6. By End User
9.2.7. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China CAR-T Cell Therapy Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product Type
9.3.1.2.2. By Tumor Type
9.3.1.2.3. By Indication
9.3.1.2.4. By Treatment Type
9.3.1.2.5. By Targeted Antigen
9.3.1.2.6. By End User
9.3.2. Japan CAR-T Cell Therapy Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product Type
9.3.2.2.2. By Tumor Type
9.3.2.2.3. By Indication
9.3.2.2.4. By Treatment Type
9.3.2.2.5. By Targeted Antigen
9.3.2.2.6. By End User
9.3.3. India CAR-T Cell Therapy Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product Type
9.3.3.2.2. By Tumor Type
9.3.3.2.3. By Indication
9.3.3.2.4. By Treatment Type
9.3.3.2.5. By Targeted Antigen
9.3.3.2.6. By End User
9.3.4. Australia Global CAR-T Cell Therapy Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Type
9.3.4.2.2. By Product Type
9.3.4.2.3. By Technology
9.3.4.2.4. By Duration
9.3.4.2.5. By Application
9.3.4.2.6. By End User
9.3.5. South Korea Global CAR-T Cell Therapy Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Type
9.3.5.2.2. By Product Type
9.3.5.2.3. By Technology
9.3.5.2.4. By Duration
9.3.5.2.5. By Application
9.3.5.2.6. By End User
10. South America CAR-T Cell Therapy Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product Type
10.2.2. By Tumor Type
10.2.3. By Indication
10.2.4. By Treatment Type
10.2.5. By Targeted Antigen
10.2.6. By End User
10.2.7. By Country
10.3. South America: Country Analysis
10.3.1. Brazil CAR-T Cell Therapy Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Product Type
10.3.1.2.3. By Technology
10.3.1.2.4. By Duration
10.3.1.2.5. By Application
10.3.1.2.6. By End User
10.3.2. Argentina CAR-T Cell Therapy Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Product Type
10.3.2.2.3. By Technology
10.3.2.2.4. By Duration
10.3.2.2.5. By Application
10.3.2.2.6. By End User
10.3.3. Colombia CAR-T Cell Therapy Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Product Type
10.3.3.2.3. By Technology
10.3.3.2.4. By Duration
10.3.3.2.5. By Application
10.3.3.2.6. By End User
11. Middle East & Africa CAR-T Cell Therapy Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Product Type
11.2.2. By Tumor Type
11.2.3. By Indication
11.2.4. By Treatment Type
11.2.5. By Targeted Antigen
11.2.6. By End User
11.2.7. By Country
11.3. Middle East & Africa: Country Analysis
11.3.1. Israel CAR-T Cell Therapy Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Type
11.3.1.2.2. By Product Type
11.3.1.2.3. By Technology
11.3.1.2.4. By Duration
11.3.1.2.5. By Application
11.3.1.2.6. By End User
11.3.2. Saudi Arabia CAR-T Cell Therapy Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Type
11.3.2.2.2. By Product Type
11.3.2.2.3. By Technology
11.3.2.2.4. By Duration
11.3.2.2.5. By Application
11.3.2.2.6. By End User
11.3.3. UAE Global CAR-T Cell Therapy Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Type
11.3.3.2.2. By Product Type
11.3.3.2.3. By Technology
11.3.3.2.4. By Duration
11.3.3.2.5. By Application
11.3.3.2.6. By End User
11.3.4. South Africa CAR-T Cell Therapy Market Outlook
11.3.4.1. Market Size & Forecast
11.3.4.1.1. By Value
11.3.4.2. Market Share & Forecast
11.3.4.2.1. By Type
11.3.4.2.2. By Product Type
11.3.4.2.3. By Technology
11.3.4.2.4. By Duration
11.3.4.2.5. By Application
11.3.4.2.6. By End User
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
14. Competitive Landscape
14.1. Competition Outlook
14.2. Company Profiles
14.2.1. Gilead Sciences, Inc
14.2.2. Novartis International AG
14.2.3. Bristol Myers Squibb Co.
14.2.4. AbbVie Inc.
14.2.5. Cellectis SA
14.2.6. Amgen Inc
14.2.7. Pfizer Inc.
14.2.8. Merck & Co. Inc.
14.2.9. Intellia Therapeutics Inc.
14.2.10. Poseida Therapeutics Inc
14.2.11. Johnson & Johnson
14.2.12. Allogene Therapeutics Inc
14.2.13. Autolus Therapeutics PLC
14.2.14. Humanigen, Inc.
14.2.15. Sangamo Therapeutics, Inc.
15. Strategic Recommendations

List of Figures

Figure 1: Global CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
Figure 2: Global CAR-T Cell Therapy Market Share, By Product Type, By Value, 2017-2027F
Figure 3: Global CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
Figure 4: Global CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
Figure 5: Global CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
Figure 6: Global CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
Figure 7: Global CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
Figure 8: Global CAR-T Cell Therapy Market Share, By Region, By Value, 2017-2027F
Figure 9: Global CAR-T Cell Therapy Market Share, By Company, By Value, 2021
Figure 10: Global CAR-T Cell Therapy Market Map, By Product Type, Market Size (USD Million) & Growth Rate (%), 2021
Figure 11: Global CAR-T Cell Therapy Market Map, By Indication, Market Size (USD Million) & Growth Rate (%), 2021
Figure 12: Global CAR-T Cell Therapy Market Map, By Region, Market Size (USD Million) & Growth Rate (%), 2021
Figure 13: North America CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
Figure 14: North America CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
Figure 15: North America CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
Figure 16: North America CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
Figure 17: North America CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
Figure 18: North America CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
Figure 19: North America CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2027F
Figure 20: United States CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
Figure 21: United States CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
Figure 22: United States CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
Figure 23: United States CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
Figure 24: United States CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
Figure 25: United States CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
Figure 26: Canada CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
Figure 27: Canada CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
Figure 28: Canada CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
Figure 29: Canada CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
Figure 30: Canada CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
Figure 31: Canada CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
Figure 32: Mexico CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
Figure 33: Mexico CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
Figure 34: Mexico CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
Figure 35: Mexico CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
Figure 36: Mexico CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
Figure 37: Mexico CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
Figure 38: Europe CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
Figure 39: Europe CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
Figure 40: Europe CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
Figure 41: Europe CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
Figure 42: Europe CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
Figure 43: Europe CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
Figure 44: Europe CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2027F
Figure 45: Germany CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
Figure 46: Germany CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
Figure 47: Germany CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
Figure 48: Germany CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
Figure 49: Germany CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
Figure 50: Germany CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
Figure 51: France CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
Figure 52: France CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
Figure 53: France CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
Figure 54: France CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
Figure 55: France CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
Figure 56: France CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
Figure 57: Switzerland CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
Figure 58: Switzerland CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
Figure 59: Switzerland CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
Figure 60: Switzerland CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
Figure 61: Switzerland CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
Figure 62: Switzerland CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
Figure 63: United Kingdom CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
Figure 64: United Kingdom CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
Figure 65: United Kingdom CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
Figure 66: United Kingdom CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
Figure 67: United Kingdom CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
Figure 68: United Kingdom CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
Figure 69: Italy CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
Figure 70: Italy CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
Figure 71: Italy CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
Figure 72: Italy CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
Figure 73: Italy CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
Figure 74: Italy CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
Figure 75: Spain CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
Figure 76: Spain CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
Figure 77: Spain CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
Figure 78: Spain CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
Figure 79: Spain CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
Figure 80: Spain CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
Figure 81: Asia-Pacific CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
Figure 82: Asia-Pacific CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
Figure 83: Asia-Pacific CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
Figure 84: Asia-Pacific CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
Figure 85: Asia-Pacific CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
Figure 86: Asia-Pacific CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
Figure 87: Asia-Pacific CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2027F
Figure 88: China CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
Figure 89: China CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
Figure 90: China CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
Figure 91: China CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
Figure 92: China CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
Figure 93: China CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
Figure 94: Japan CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
Figure 95: Japan CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
Figure 96: Japan CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
Figure 97: Japan CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
Figure 98: Japan CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
Figure 99: Japan CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
Figure 100: India CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
Figure 101: India CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
Figure 102: India CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
Figure 103: India CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
Figure 104: India CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
Figure 105: India CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
Figure 106: Australia CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
Figure 107: Australia CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
Figure 108: Australia CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
Figure 109: Australia CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
Figure 110: Australia CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
Figure 111: Australia CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
Figure 112: South Korea CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
Figure 113: South Korea CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
Figure 114: South Korea CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
Figure 115: South Korea CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
Figure 116: South Korea CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
Figure 117: South Korea CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
Figure 118: South America CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
Figure 119: South America CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
Figure 120: South America CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
Figure 121: South America CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
Figure 122: South America CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
Figure 123: South America CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
Figure 124: South America CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2027F
Figure 125: Brazil CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
Figure 126: Brazil CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
Figure 127: Brazil CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
Figure 128: Brazil CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
Figure 129: Brazil CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
Figure 130: Brazil CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
Figure 131: Argentina CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
Figure 132: Argentina CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
Figure 133: Argentina CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
Figure 134: Argentina CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
Figure 135: Argentina CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
Figure 136: Argentina CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
Figure 137: Colombia CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
Figure 138: Colombia CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
Figure 139: Colombia CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
Figure 140: Colombia CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
Figure 141: Colombia CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
Figure 142: Colombia CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
Figure 143: Middle East & Africa CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
Figure 144: Middle East & Africa CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
Figure 145: Middle East & Africa CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
Figure 146: Middle East & Africa CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
Figure 147: Middle East & Africa CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
Figure 148: Middle East & Africa CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
Figure 149: Middle East & Africa CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2027F
Figure 150: Israel CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
Figure 151: Israel CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
Figure 152: Israel CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
Figure 153: Israel CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
Figure 154: Israel CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
Figure 155: Israel CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
Figure 156: Saudi Arabia CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
Figure 157: Saudi Arabia CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
Figure 158: Saudi Arabia CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
Figure 159: Saudi Arabia CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
Figure 160: Saudi Arabia CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
Figure 161: Saudi Arabia CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
Figure 162: UAE CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
Figure 163: UAE CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
Figure 164: UAE CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
Figure 165: UAE CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
Figure 166: UAE CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
Figure 167: UAE CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F
Figure 168: South Africa CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2027F
Figure 169: South Africa CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2027F
Figure 170: South Africa CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2027F
Figure 171: South Africa CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2027F
Figure 172: South Africa CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2027F
Figure 173: South Africa CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2027F

List of Tables

Table 1: Global Cancer Statistics, 2020
Table 2: Total Number of New Cancer Cases and Deaths Reported Globally, By Type, 2020
Table 3: Details of FDA Approved CAR-T Cell Therapies (As of February 2022)
Table 4: North America Cancer Statistics, 2020
Table 5: Total Number of New Cancer Cases and Deaths Reported in North America, By Type, 2020
Table 6: Europe Cancer Statistics, 2020
Table 7: Total Number of New Cancer Cases and Deaths Reported in Europe, By Type, 2020
Table 8: Asia-Pacific Cancer Statistics, 2020
Table 9: Total Number of New Cancer Cases and Deaths Reported in Asia Pacific, By Type, 2020
Table 10: South America Cancer Statistics, 2020
Table 11: Total Number of New Cancer Cases and Deaths Reported in South America, By Type, 2020
Table 12: Middle East & Africa Cancer Statistics, 2020
Table 13: Total Number of New Cancer Cases and Deaths Reported in Middle East, By Type, 2020
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Gilead Sciences, Inc
  • Novartis International AG
  • Bristol Myers Squibb Co.
  • AbbVie Inc.
  • Cellectis SA
  • Amgen Inc
  • Pfizer Inc.
  • Merck & Co. Inc.
  • Intellia Therapeutics Inc.
  • Poseida Therapeutics Inc
  • Johnson & Johnson
  • Allogene Therapeutics Inc
  • Autolus Therapeutics PLC
  • Humanigen, Inc.
  • Sangamo Therapeutics, Inc.
Note: Product cover images may vary from those shown